Navigation Links
Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
Date:5/6/2009

CHADDS FORD, Pa., May 6 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it will present at the Bank of America and Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, 2009 at 12:40 pm Eastern Time. Dave Holveck, President and Chief Executive Officer of Endo, will review the company's products and development programs.

The presentation will be webcast live and can be accessed from Endo's website at www.endo.com under the investors section.

ABOUT ENDO

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP).Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and Voltaren(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by Novartis AG; Sanctura(R) and its XR version for treatment of overactive bladder, Vantas(R) for the palliative treatment of advanced prostate cancer, and Supprelin(R) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the acquisition of Indevus, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; competition in our industry, including for branded and generic products, and in connection with our acquisition of rights to assets, including intellectual property; government regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of controlled substances in many of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves; our ability to protect our proprietary technology; our ability to successfully implement our in-licensing and acquisition strategy; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by the government; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total net sales; a determination by a regulatory agency that we are engaging in inappropriate sales or marketing activities, including promoting the "off-label" use of our products; the loss of branded product exclusivity periods and related intellectual property; and exposure to securities that are subject to market risk including auction-rate securities the market for which is currently illiquid; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on March 2, 2009. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CorMatrix Cardiovascular to Present on its ECM Technology(TM) at the Annual Advanced Cardiac Techniques in Surgery (ACTS) Symposium in New York, N.Y.
2. Carriage Services to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
3. Align Technology Executives to Present at Upcoming Financial Conferences
4. AMN Healthcare Services to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference and at the Robert W. Baird 2009 Growth Stock Conference
5. Medco to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
6. ResMed Inc. to Present at Upcoming Healthcare Conferences in May
7. IPC The Hospitalist Company, Inc. to Present at Deutsche Banks 34th Annual Health Care Conference
8. HBO, the Arizona Alzheimers Consortium and the Alzheimers Association, Desert Southwest Chapter Present a Free Advance Screening of THE ALZHEIMERS PROJECT: Momentum In Science
9. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
10. China Medicine to Present at CCG IRs China Rising Conference in New York
11. Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a ... its 60-day free trial program for all of the company’s desktop riser products. ... truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced dual ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame ... (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking ... prescription drug plan (Part D) need to make changes during this period order for ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 Lianluo Smart ... or "the Company") which develops, markets and sells ... China and international markets, ... Diagnosis and Treatment New Progress Forum, co-hosted by ... Guangdong Province , Guangdong Provincial People,s Hospital ...
(Date:12/2/2016)... , December 2, 2016 On ... down 1.36%; the Dow Jones Industrial Average edged 0.36% higher, ... 2,191.08, down 0.35%. Losses were broad based as six out ... has initiated research reports on the following Services equities: Myriad ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... OLD LYME, Conn. , Dec. 1, 2016 /PRNewswire/ ... consulting, has announced the honor of being selected as ... that include: Simpson Healthcare Executives Website at the PLATINUM ... Directed Conversations Training Module at the GOLD Level, and ... At Simpson Healthcare Executives, we are ...
Breaking Medicine Technology: